Study on Epcoritamab with Other Cancer Treatments for Adults with Non-Hodgkin Lymphoma

Sponsor: Genmab

Sponsor score: 40
Inactive

ClinicalTrials ID:NCT05283720

Provider View

This clinical trial is testing the safety and effects of a new drug, epcoritamab, combined with other cancer treatments in adults with Non-Hodgkin Lymphoma (NHL). The study will monitor side effects and changes in the disease.

Patient Parameters

Program Overview

B-cell Lymphoma is a rare and aggressive cancer affecting certain white blood cells. This study aims to test the safety and tolerability of a new drug, epcoritamab, when used with other cancer treatments in adults with Non-Hodgkin Lymphoma (NHL). Researchers will look at side effects and how the disease responds to the treatment. Epcoritamab is an experimental drug being developed for NHL. Participants will be divided into groups, each receiving different treatment combinations based on their eligibility. Around 622 adults with NHL will participate in this study at 100 locations worldwide. Participants will receive epcoritamab through an injection under the skin in cycles of 28, 21, or 56 days, along with other cancer drugs. The study involves regular visits to a hospital or clinic for medical check-ups, blood tests, questionnaires, and monitoring of side effects.

Eligibility Criteria

Inclusion Criteria

  • Diagnosed with specific types of Non-Hodgkin Lymphoma, such as Diffuse Large B-Cell Lymphoma (DLBCL), Follicular Lymphoma (FL), or Mantle Cell Lymphoma (MCL).
  • Cancer must be confirmed by a recent biopsy and show certain markers like CD20+.
  • Must have at least one measurable tumor that can be seen on a PET/CT scan.
  • Must be in relatively good health with an ECOG performance status of 0 to 2, except for certain groups where it must be 0 to 1.

Exclusion Criteria

  • Have previously been treated with epcoritamab or similar drugs targeting CD3 and CD20.
  • Have unresolved side effects from previous cancer treatments, except for hair loss. Other health criteria must also be met.

Get This Program In Your Inbox

Receive detailed information about this treatment opportunity to review with your healthcare provider.